Zevra's ROIC of -19.57% Beats Peers with Superior Capital Efficiency
ZVRA•Zevra Therapeutics' ROIC is -19.57% versus a WACC of 8.71%, yielding a ROIC/WACC ratio of -2.25. This outpaces Inhibikase Therapeutics at -3.79 and Inozyme Pharma at -5.33, showing Zevra limits value destruction compared with its R&D peers.
1. Company Overview
Zevra Therapeutics specializes in developing treatments for rare diseases such as idiopathic hypersomnia and stimulant use disorder, pursuing R&D-intensive programs with potential long-term revenue once products reach the market.
2. Financial Efficiency Metrics
The company’s return on invested capital stands at -19.57% against a weighted average cost of capital of 8.71%, resulting in a ROIC/WACC ratio of -2.25 and indicating current value destruction as heavy research spending precedes commercialization.
3. Peer Comparison
Zevra’s ROIC/WACC ratio of -2.25 outperforms Inhibikase Therapeutics at -3.79 and Inozyme Pharma at -5.33, suggesting Zevra destroys capital at a slower rate than its closest R&D-focused competitors.
